

Hereditary Cancer

Highlighted fields are required information

PATIENT INFORMATION			CLIENT INFORMATION	
Last Name	First Name	MI	Client Name	
Address			Client ID	
City	State	Zip		
Phone	Date of Birth (MM/DD/YYYY)	Sex Assigned at Birth <input type="radio"/> Male <input type="radio"/> Female <input type="radio"/> Unknown		
Patient MR#				

SAMPLE INFORMATION	
SAMPLE DRAW DATE(MM/DD/YYYY)	SAMPLE TYPE <input type="radio"/> Blood <input type="radio"/> Saliva swab <input type="radio"/> Extracted DNA & DNA Source (Blood, Buccal, Tissue, Fibroblast): _____ <input type="radio"/> Other: _____

I have read the informed consent document and I give permission to Fulgent Genetics and its affiliates to perform genetic testing as described. I also give permission for my specimen and clinical information to be used in de-identified studies and for publication, if appropriate at Fulgent Genetics and its affiliates. My name or other personal identifying information will not be used in or linked to the results of any studies and publications. More information is available at www.fulgentgenetics.com/policies/privacy-policy.

- Opt out of research
- Check this box if you are a New York state resident and give permission for Fulgent to retain any remaining sample longer than 60 days after the completion of testing.

X	_____	_____
Patient/Guardian Signature (Required for billing purposes)		Date (MM/DD/YYYY)

PROVIDER INFORMATION			
INSTITUTIONAL PRACTICE NAME	PROVIDER LAST NAME	PROVIDER FIRST NAME	
PROVIDER NPI #	PROVIDER TITLE (MD, DO, GC)	PROVIDER PHONE	FAX REPORT TO
PRIMARY CONTACT/GENETIC COUNSELOR	PRIMARY CONTACT PHONE/FAX	PRIMARY CONTACT EMAIL	

I attest that the patient has received and read the Fulgent informed consent document, or has had it read to him or her, and that I have fully informed the patient about the purpose, capabilities, and limitations of the ordered test. The patient has voluntarily given his or her full consent for the ordered test and a signed copy of this consent is available on file. Any Fulgent informed consent that the patient agrees to at a later date will supersede and replace this informed consent.

STATEMENT OF MEDICAL NECESSITY
By signing below, I, the ordering Medical Provider, confirm that testing is medically necessary and that test results may impact medical management for the patient.

X	_____	_____
Ordering Provider Signature (Required for billing purposes)		Date (MM/DD/YYYY)

INSURANCE/BILLING INFORMATION			
Please attach insurance cards for billing • Attach front and back of all insurance cards, ABN, medical criteria form			
By signing above, the patient or payor authorizes Fulgent Genetics and its affiliates to contact them directly, and use the provided billing instructions to bill the indicated method.			
ICD-10 CODE	REFERRAL/PRIOR AUTH	FULGENT BENEFITS ID#	
PRIMARY INSURANCE ID	INSURANCE NAME	STATE	GROUP
INSURANCE PLAN	NAME OF INSURED	RELATION TO PATIENT	INSURANCE PHONE #
SECONDARY INSURANCE ID	INSURANCE NAME	STATE	GROUP
INSURANCE ID	NAME OF INSURED	RELATION TO PATIENT	DATE OF BIRTH (MM/DD/YYYY)

SELF-PAY			
By signing above, the patient or payor authorizes Fulgent Genetics and its affiliates to contact them directly, and use the provided billing instructions to bill the indicated method.			
<input type="radio"/> Use patient information above for billing <input type="radio"/> Use information below for billing			
PAYOR LAST NAME	PAYOR FIRST NAME	PHONE	EMAIL
ADDRESS	CITY	STATE	POSTAL CODE
COUNTRY			

INSTITUTION BILLING			
INSTITUTIONAL PRACTICE NAME	ATTENTION TO	PHONE	EMAIL
ADDRESS	CITY	STATE	POSTAL CODE
COUNTRY			

Hereditary Cancer

Highlighted fields are required information

SELECT TEST PANEL Please select only one test panel

COMPREHENSIVE

Full Comprehensive Panel (FT-TP00048) Includes subpanels listed below.

BREAST & OVARIAN CANCERS

- BRCA1 & BRCA2 Focus Panel (FT-TP01125)
- Breast Cancer Comprehensive Panel (FT-TP00043)
- Ovarian Cancer Comprehensive Panel (FT-TP00053)
- Breast & Ovarian Comprehensive Panel (FT-TP00461)

COLORECTAL CANCERS

- Colorectal Comprehensive Panel (FT-TP00044)
- Lynch Syndrome Focus Panel (FT-TP01543)

OTHERS

- Endometrial Cancer Comprehensive Panel (FT-TP00046)
- Gastric Cancer Comprehensive Panel (FT-TP00049)
- Hematologic Malignancy Comprehensive Panel (FT-TP00050)
- Multiple Endocrine Neoplasia Comprehensive Panel (FT-TP00182)
- Nervous System/Brain Comprehensive Panel (FT-TP00052)
- Prostate Cancer Comprehensive Panel (FT-TP00056)

All genes included on the cancer-specific panels are included on the full comprehensive panel.

SINGLE GENE OR KNOWN MUTATION & ADDITIONAL REQUESTS

Single Gene or Known Mutation Test Panel (FT-TP00045) Indicate below, single gene from the Comprehensive Panel **OR** gene and variant. Standard HGVS variant nomenclature is required for known mutation testing (e.g. c.nomen, transcript number)

Other Test Panels

TEST OPTION

Exclude VUS

PATIENT CLINICAL HISTORY Check all that apply

No personal history of cancer

INDICATIONS FOR TESTING Check all that apply

Diagnostic Family History Family Variant Presymptomatic Other: _____

CANCER/TUMOR TYPE	AGE OF ONSET	PATHOLOGY AND OTHER INFO
<input type="checkbox"/> Brain		
<input type="checkbox"/> Breast		ER: <input type="radio"/> POS(+) <input type="radio"/> NEG(-) <input type="radio"/> UNK(?) PR: <input type="radio"/> POS(+) <input type="radio"/> NEG(-) <input type="radio"/> UNK(?) HER2/neu: <input type="radio"/> POS(+) <input type="radio"/> NEG(-) <input type="radio"/> UNK(?)
<input type="checkbox"/> 2nd Primary Breast		ER: <input type="radio"/> POS(+) <input type="radio"/> NEG(-) <input type="radio"/> UNK(?) PR: <input type="radio"/> POS(+) <input type="radio"/> NEG(-) <input type="radio"/> UNK(?) HER2/neu: <input type="radio"/> POS(+) <input type="radio"/> NEG(-) <input type="radio"/> UNK(?)
<input type="checkbox"/> Colorectal		Location: _____
<input type="checkbox"/> Hematologic		
<input type="checkbox"/> GI polyps		<input type="checkbox"/> Adenomatous <input type="checkbox"/> Other: Number of polyp(s)#: _____

CANCER/TUMOR TYPE	AGE OF ONSET	PATHOLOGY AND OTHER INFO
<input type="checkbox"/> Melanoma		
<input type="checkbox"/> Ovarian		<input type="checkbox"/> Fallopian Tube <input type="checkbox"/> Serous <input type="checkbox"/> Clear Cell <input type="checkbox"/> Primary Peritoneal <input type="checkbox"/> Mucinous <input type="checkbox"/> Borderline/LMP <input type="checkbox"/> Endometrioid <input type="checkbox"/> Other: _____
<input type="checkbox"/> Pancreatic		
<input type="checkbox"/> Prostate		Gleason Score: _____ Metastatic <input type="radio"/> Yes <input type="radio"/> No
<input type="checkbox"/> Uterine		
<input type="checkbox"/> Other Cancer		

CLINICAL HISTORY/SUSPECTED DIAGNOSIS

Please attach copy of recent CBC, copy of doctor's notes/clinical history, pathology reports, and any relevant test results

PATIENT TESTING HISTORY Please attach relevant reports

Germline testing results:

Microsatellite Instability (MSI) results:

Immunohistochemistry (IHC) results:

Somatic testing/Tumor profile results:

Other, specify:

FAMILY HISTORY Attach pedigree and additional pages as needed

FAMILY MEMBER NAME (1)	RELATION TO PATIENT	SEX ASSIGNED AT BIRTH
		<input type="radio"/> Male <input type="radio"/> Female <input type="radio"/> Unknown
DIAGNOSIS AND/OR SYMPTOMS	AGE OF ONSET	DATE OF BIRTH (MM/DD/YYYY)
FAMILY MEMBER NAME (2)	RELATION TO PATIENT	SEX ASSIGNED AT BIRTH
		<input type="radio"/> Male <input type="radio"/> Female <input type="radio"/> Unknown
DIAGNOSIS AND/OR SYMPTOMS	AGE OF ONSET	DATE OF BIRTH (MM/DD/YYYY)

Panels & Gene List

Visit www.FulgentOncology.com for the most up-to-date panel and gene list information.

PANEL	GENES TESTED
Full Comprehensive Panel (FT-TP00048)	<i>ABRAXAS1, AIP, AKT1, ALK, ANKRD26, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CEP57, CHEK2, CTC1, CTNNA1, CTRC, CYLD, DDB2, DDX41, DICER1, DIS3L2, DKC1, EGFR, EGLN1, ELANE, ENG, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EXO1, EXT1, EXT2, EZH2, FAN1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GALNT12, GATA2, GEN1, GPC3, GREM1, HOXB13, HRAS, IKZF1, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NHP2, NOPI0, NTHL1, PALB2, PALLD, PAX5, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POLH, POT1, PRKAR1A, PRSS1, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL, RECQL4, REST, RET, RHBDF2, RNF43, RPS20, RUNX1, SAMD9L, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLC45A2, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, SRP72, STK11, SUFU, TERC, TERT, TGFBRI, TINF2, TMEM127, TP53, TRIP13, TSC1, TSC2, TYR, VHL, WRAP53, WRN, WT1, XPA, XPC, XRCC2</i> (154 genes)
BRCA1 & BRCA2 Focus Panel (FT-TP01125)	<i>BRCA1, BRCA2</i> (2 genes)
Breast Cancer Comprehensive Panel (FT-TP00043)	<i>ABRAXAS1, AKT1, ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, CTNNA1, DICER1, EPCAM, FANCC, FANCM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PIK3CA, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SDHB, SDHD, SMARCA4, STK11, TP53, XRCC2</i> (37 genes)
Breast & Ovarian Comprehensive Panel (FT-TP00461)	<i>ABRAXAS1, AKT1, ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, CTNNA1, DICER1, EPCAM, FANCC, FANCM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PIK3CA, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SDHB, SDHD, SMARCA4, STK11, TP53, XRCC2</i> (37 genes)
Ovarian Cancer Comprehensive Panel (FT-TP00053)	<i>ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, EPCAM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, RAD51C, RAD51D, SMARCA4, STK11, TP53</i> (20 genes)
Colorectal Comprehensive Panel (FT-TP00044)	<i>APC, ATM, AXIN2, BLM, BMPR1A, CDH1, CHEK2, CTNNA1, EPCAM, FAN1, GALNT12, GREM1, MBD4, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, RNF43, RPS20, SMAD4, STK11, TP53</i> (29 genes)
Lynch Syndrome Focus Panel (FT-TP01543)	<i>EPCAM, MLH1, MSH2, MSH6, PMS2</i> (5 genes)
Gastric Cancer Comprehensive Panel (FT-TP00049)	<i>APC, BMPR1A, BRCA1, BRCA2, CDH1, CTNNA1, EPCAM, KIT, MLH1, MSH2, MSH6, NF1, PDGFRA, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53</i> (22 genes)
Endometrial Cancer Comprehensive Panel (FT-TP00046)	<i>BRCA1, BRCA2, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMARCA4, STK11, TP53</i> (15 genes)
Multiple Endocrine Neoplasia Comprehensive Panel (FT-TP00182)	<i>AIP, CASR, CDC73, CDKN1B, MEN1, RET</i> (6 genes)
Hematologic Malignancy Comprehensive Panel (FT-TP00050)	<i>ANKRD26, ATM, BLM, CEBPA, DDX41, EPCAM, GATA2, HRAS, IKZF1, MLH1, MSH2, MSH6, NBN, NF1, PAX5, PMS2, RUNX1, SAMD9L, SRP72, TERC, TERT, TP53</i> (22 genes)
Nervous System/Brain Comprehensive Panel (FT-TP00052)	<i>AIP, ALK, APC, ATM, CDKN1B, CDKN2A, DICER1, EPCAM, HRAS, KIF1B, LZTR1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, POT1, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL</i> (32 genes)
Prostate Cancer Comprehensive Panel (FT-TP00056)	<i>ABRAXAS1, ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, GEN1, HOXB13, MLH1, MRE11, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53</i> (20 genes)
Single Gene or Known Mutation Test (FT-TP00045)	Indicate single gene from the Comprehensive Panel OR gene and variant in the "Test Specifics" section of the test requisition form.